Venture Life Share Discussion Threads

[apad] 20/11/2016 17:42

BVXP
100k out of 500k I believe, dacian.
Be interesting to see the ordinary trading range tomorrow.
apad

[apad] 18/11/2016 09:06

Top-sliced some TRCS and switched into BVXP.
apad

[redartbmud] 18/11/2016 08:03

Snap

Great minds work alike.

Oxig moved up as a consequence.

red

[apad] 18/11/2016 08:00

I know that feeling, red :-)

I'm beginning to classify 'lumpy orders, good technology, no growth vector, companies'
Maybe SRT/ZYT. OXIG bigger, but similar maybe.

apad

[redartbmud] 18/11/2016 07:54

Update:
Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the disposal of Oxford Instruments Superconducting Wire LLC ("OST") to Bruker Energy and Supercon Technologies Inc ("BEST"), a subsidiary of Bruker Corporation, for a consideration of $17.5 million, payable in cash. In the transaction, BEST has acquired the entire share capital of OST from Oxford Instruments.

red

[apad] 18/11/2016 07:54

Disposal of Oxford Instruments Superconducting Wire LLC ("OST")



Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the disposal of Oxford Instruments Superconducting Wire LLC ("OST") to Bruker Energy and Supercon Technologies Inc ("BEST"), a subsidiary of Bruker Corporation, for a consideration of $17.5 million, payable in cash. In the transaction, BEST has acquired the entire share capital of OST from Oxford Instruments.



OST supplies world-leading superconducting wire for use in MRI scanners and other medical and scientific applications; it is located in Carteret, New Jersey, USA. The business was previously part of Oxford Instruments' Industrial Products division.

[redartbmud] 18/11/2016 07:52

APAD

Thanks.
slow demand for healthcare products and weakness in superconducting wire sales are expected to constrict full-year profit.
Oxford’s superconducting wire business relies on a small number of magnetic resonance imaging manufacturers as customers, so patchy revenue streams are unavoidable.

Doesn't help, if you want to love the company, does it.

red

[apad] 18/11/2016 06:49

IC on OXIG, red.

Oxford steps up R&D
Reported half-year revenue for Oxford Instruments (OXIG) benefited from foreign exchange translation effects. A 6.9 per cent contraction at constant currencies points to challenges in the technology tools company’s European and North American markets, while adjusted group profit was down 3.7 per cent on the 2015 comparative. Working capital outflows bumped up net debt by around £13m from six months earlier.
Oxford’s market valuation was relatively untroubled on the release of the figures, with a 5 per cent constant-currency increase in the order book, together with a marked rise in profitability at the highly promising nanotechnology tools segment. Management has stepped up research and development (R&D) spending by 12 per cent to £15.1m.
The nanotechnology result sweetened the pill to an extent, but slow demand for healthcare products and weakness in superconducting wire sales are expected to constrict full-year profit. Oxford’s superconducting wire business relies on a small number of magnetic resonance imaging manufacturers as customers, so patchy revenue streams are unavoidable.
N+1 Singer expects revenue of £381m for the March 2017 year-end, together with EPS of 51.5p, rising to £390m and 56.4p in the following year (up from £362m and 49.1p in FY2016).
D Management envisages a £7m translation gain to FY2018 operating profit, assuming sterling’s relative value and Oxford’s business mix remain broadly unchanged. The shares now trade at an undemanding 12 times forecast earnings, but a slowdown in academic funding across the pond and continued problems in the healthcare market will hamper near-term prospects. MR
Hold

[apad] 17/11/2016 22:30

Blimey, mod, you have a nose for the unusual.
Too generic for me, but they look interesting.
6% BVXP looks great to me. I need another 2% to get there.

P,
Antibodies are ubiquitous. I believe BVXP have a niche that they know well how to control and exploit, but that there are limitations to expansion, just as their technology does not invite competition.
In the meantime Mr BVXP is like a pig in muck.
Your graph is a problem all my shares should have :-)
I do not agree about your time observation. The 2017 loss of royalty has created a space to buy that is closing fast.

apad

[hydrus] 17/11/2016 22:28

Thanks for the reply I misunderstood your previous post

[piedro] 17/11/2016 21:24

Hydrus,

The chart was to demonstrate why I consider the shares still worth buying
at these levels and that with their royalty model the margins can only get
better in the medium term.

For the longer term, (which I prefer), I do have reservations as to whether
they will be able to maintain their supply chain or if their products will
still be in demand or have been superseded by other technologies.

I like what I see so far and do feel that I have enough time to get to know
better the company, its products and the market in which they operate.

AIMO

[hydrus] 17/11/2016 19:40

Piedro do you mind expanding on your point please? Are you worried about their gross margins being eroded for some reason?

[modform] 17/11/2016 19:27

Apad, I have a small holding in BXP very similar ticker to BVXP, the company looks cheap and the USA entry could be transformational.BVXP is now 6% of PF, so no more top up until further news.

[modform] 17/11/2016 19:19

KWS, another earning enhancing acquisition AVS, what a premium, patience paid off

[piedro] 17/11/2016 19:16

sherlychan,

This is the problem with BVXP - it's all bottom line


- AIMHO

[sherylchan] 17/11/2016 18:51

Apad et al - thanks just read thru all the BVXP mentions on the board - Apad from your first mention in 2014 n your reservations then and subsequent embrace ) - answered a few questions, thanks !

[apad] 17/11/2016 17:18

See my earlier posts on BVXP, s.
apad

[sherylchan] 17/11/2016 16:24

Apad, thanks for the reply.

Yes, I listened to the CEO in his interview after the results - the troponin is expected to yield revenue of £2m but might take 2-3 years, with a target of hopefully £800k in 2017 if as foreseen by Co., launch by 2nd half 2017.

I believe there is a sizeable seller about - maybe up to 200k shares - but I will definitely be a strong buyer in the lower 1100s (if it gets there)

Do you know if the company has any aspirations to be a bigger one e.g. via acquisitions or otherwise (the likes of ABC for instance) - as given its preference to regular dividends/special divis & retention of minimal cash - how would the company grow to say nearer the 500m cap say?

[redartbmud] 17/11/2016 16:18

APAD

Well spotted, thanks.

red

[apad] 17/11/2016 16:08

Red,

Reckon this company is the reason Renishaw pulled out of Raman for biological analysis, perhaps.
www.m2lasers.com/newsevents/news/m-squared-lasers-secures-investment-for-growth.aspx
Beautiful engineering (not quoted).

apad

[apad] 17/11/2016 16:01

I have been buying from 950 through to 1450, s.
I gave up trying to value this type of share a long time ago. It's a bet on Cardiac Troponin being transformative. Also it's ROCE is a ridiculous 47% and its free cash flow yield is over 2.8%.
Normally I would say buy the dips, but there aint gonna be any (unless the Siemens initiative fails, then it'll be a cliff)
Not much use to you I'm afraid.
apad

[sherylchan] 17/11/2016 13:32

APAD - been looking at BVXP - as I don't currently hold, my concern is buying at this level of £14+ - given just paid out special dividends, no near term news (apart from AGM early Dec) - and key concern is Henderson seem to be reducing/selling stake, I suspect they will sell down further (maybe new Fund Manager etc or on valuation grounds), and with thin liquidity, prone to large movements (up or down)

Would be interested in your view as a reasonable level to start averaging into BVXP?

thanks in advance

[redartbmud] 17/11/2016 11:13

APAD

Thanks.
Dithering on Oxig. Probably leave alone.
Getting interested in Gsk @ £15 but they immediately started moving away from me. I will bide my time. Might have jumped at £15.05

red

[apad] 17/11/2016 11:02

Looked at OXIG way back - not recently. Electron microscope heyday passed. V. Good products, but selling into an international science market that depends on good economies, and they don't wear out.

GSK will go in the opposite direction that I predict, red. It must be the potential for US pressure on pharmaceuticals, so lets buy banks story I suppose. Dollar earning must show through at some point.

TRCS reads like the last full year results, dacian. Beautifully clear numbers and sector breakdown. No new nuggets. All about potential for bought in software companies in terms of turnover and earnings. Net Operating cash flow 2014, 5.717. 2015, 5.35. 2016, 5.866. So they are coping with the lack of Framework orders. Being small, one decent piece of news on Framework or US is what is needed.
apad